The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
Quiz|Articles|August 7, 2026
OncLive Weekly News Quiz (8/7/2026): Did You Catch This Week's Melanoma, Pancreatic, Breast, and Neuroendocrine Cancer Updates?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Key Takeaways
- ”, complete sentences, no repetitive openings).
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
The FDA granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev; RP1) plus nivolumab (Opdivo) for adults with unresectable advanced cutaneous melanoma that progressed on anti–PD-1 therapy, based on the phase 1/2 IGNYTE trial (NCT03767348). What type of agent is RP1?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Olomorasib earned breakthrough therapy status as a monotherapy for adults with previously treated, KRAS G12C-mutant advanced pancreatic cancer.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts reveal their top picks for gastrointestinal oncology presentations from the 2026 ASCO Annual Meeting.
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
Read a refresh of breast cancer FDA news from July, including the first approval of a pan-PI3K/mTOR inhibitor combination and a pegfilgrastim biosimilar.
The FDA granted accelerated approval to RP1 plus nivolumab in anti–PD-1 therapy–pretreated advanced melanoma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Accelerated Approval to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy
2
FDA Flashback: Breast Cancer Decisions and News From July 2026
3
Dr Wong on the FDA Approval of Vusolimogene Oderparepvec-wtpg Plus Nivolumab in Melanoma
4
Dr Brufsky on the FDA Approval of Gedatolisib Plus Fulvestrant ± Palbociclib in PIK3CA Wild-Type Breast Cancer
5